In biotechnology, the journey from discovery to market can appear insurmountable unless you are a major pharmaceutical company. Increasingly, technology is allowing for the development of promising therapeutics in small labs, especially for rare and orphan diseases that are often overlooked by large drugmakers. Unfortunately, these small labs are usually without the means and resources to produce their potential cures at scale.
That's where Contract Development and Manufacturing Organizations (CDMOs) such as Batavia Biosciences come in. By partnering with CDMOs, these small companies can gain expertise as well as infrastructure and regulatory compliance capabilities, thereby accelerating their journey toward clinical evaluation and eventual commercialization. The number of CDMOs greatly increased during the Covid-19 pandemic, but Batavia is no newcomer. It has helped clients in the arduous journey of bringing viral vaccines, viral vectors, proteins and antibodies to fruition for 14 years.
